Effects of a Combination of Bifidobacterium Longum Subsp. Longum Strains on Stress and Related Health Outcomes in Young Adult
Effect of Bifidobacterium Longum Subsp. Longum Combination Intervention on Stress Status and Related Health Outcomes: A Randomized, Double-Blind, Placebo-Controlled Clinical Study
This study is a prospective, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the effects of a combination of Bifidobacterium longum subsp. longum strains on stress-related health outcomes in adults. The study plans to enroll 126 adults experiencing stress-related problems, who will be randomly assigned in equal proportions to either the probiotic group or the placebo group and will receive the assigned intervention for 8 weeks. Participants will complete the scheduled study visits and assessments.
The study will systematically evaluate the principal health concerns of young adults experiencing high levels of stress through multiple approaches, including subjective questionnaire assessments, biological sample testing, and gut microbiome analysis. The main assessments will include a comparison of changes in stress status before and after the intervention between the probiotic and placebo groups using validated psychological assessment instruments. The effects of the intervention on sleep quality, quality of life, and related emotional states will also be evaluated. Sleep quality and quality of life will be assessed using validated assessment instruments.
To further investigate the potential biological mechanisms, stool samples will be collected from participants for gut microbiome metagenomic analysis to characterize changes in microbial composition and functional features. Laboratory-based assays will also be used to measure stress-, immune-, and inflammation-related biomarkers. This study is expected to provide preliminary evidence supporting the clinical application of microbiota-targeted interventions based on modulation of the gut-brain axis in populations experiencing high levels of stress.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Yuan Jie
- Telefonnummer: +86 198 2187 2781
- E-Mail: peanut.yuan@diprobio.com
Studienorte
-
-
Gansu
-
Lanzhou, Gansu, China, 730030
- Northwest Minzu University
-
Kontakt:
- Jie Yuan
- Telefonnummer: +86 13308178331
- E-Mail: 13308178331@163.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults aged 18-65 years.
- Perceived Stress Scale-10 (PSS-10) score ≥ 14.
- Voluntary participation in the study and provision of written informed consent before any study procedures begin.
Exclusion Criteria:
- Use of probiotic supplements or probiotic-containing products within 4 weeks before enrollment.
- Use of antibiotics or systemic glucocorticoids within 4 weeks before enrollment.
- Current or previous diagnosis of psychiatric disorders (e.g., schizophrenia or major depressive disorder), epilepsy, major endocrine disorders, active inflammatory bowel disease or other severe gastrointestinal disorders, or severe sleep disturbances requiring treatment adjustment.
- Use of medications or dietary supplements that may affect the gut-brain axis, sleep, mood, or stress status assessment within 4 weeks before enrollment, including but not limited to sedative-hypnotics, anxiolytics, antidepressants, antipsychotics, mood stabilizers, and supplements with sleep-inducing, sedative, or stress-relieving effects (e.g., magnesium-containing supplements).
- Pregnant or breastfeeding women.
- Known allergy to the study product or any of its components.
- Smoking or alcohol consumption on the day of the study visit or within 48 hours before the visit.
- Participation in other clinical intervention studies involving drugs, dietary supplements, probiotics, or prebiotics within the past 3 months.
- Insufficient compliance, as judged by the investigator, to complete sample collection or study-related documentation as required by the study protocol.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Probiotic group
Participants receive Bifidobacterium longum subspecies combination formulation. |
Participants receive an oral probiotic combination formulation according to the study protocol for the duration of the intervention. |
|
Placebo-Komparator: Placebo group
Participants receive a matching placebo formulation. |
Participants receive a matching placebo formulation according to the same administration schedule as the probiotic intervention. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Depression Anxiety Stress Scales-42 (DASS-42) Stress Subscale Score
Zeitfenster: Baseline, Week 4, Week 8
|
Stress levels will be assessed using the Stress subscale of the 42-item Depression Anxiety Stress Scales (DASS-42). The subscale consists of 14 items, each scored from 0 to 3. The total Stress subscale score ranges from 0 to 42, with higher scores indicating greater stress severity. Raw scores will be reported at each assessment time point. |
Baseline, Week 4, Week 8
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pittsburgh Sleep Quality Index (PSQI) Global Score
Zeitfenster: Baseline, Week 4, Week 8
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The global score is calculated by summing seven component scores, each ranging from 0 to 3. The total global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Raw PSQI global scores will be reported at each assessment time point. |
Baseline, Week 4, Week 8
|
|
WHOQOL-BREF Physical Health Domain Score
Zeitfenster: Baseline, Week 4, Week 8
|
Quality of life in the physical health domain will be assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire. Domain scores will be transformed to a scale ranging from 0 to 100, with higher scores indicating better quality of life in the corresponding domain. Raw transformed domain scores will be reported at each assessment time point. |
Baseline, Week 4, Week 8
|
|
Relative Abundance of Prespecified Gut Microbial Taxa
Zeitfenster: Baseline, Week 4, Week 8
|
The relative abundance of prespecified gut microbial taxa will be assessed using shotgun metagenomic sequencing of fecal samples. Relative abundance will be expressed as a percentage of the total taxonomic abundance assigned to the selected taxa at each assessment time point. |
Baseline, Week 4, Week 8
|
|
Gut stress and immune biomarkers
Zeitfenster: Baseline, Week 4, Week 8
|
Baseline, Week 4, Week 8
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- XBMU-YX-20260038
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .